Dr. Jones is Director, CRUK Clinial Trials Unit, Beatson West of Scotland Cancer Centre. After undergraduate training at the Universities of Oxford and Edinburgh, Rob moved to Glasgow to train in internal medicine and then Medical Oncology. He completed PhD in the Frame Lab at the Beatson Institute for Cancer research, where he studied the role of Src kinase in metastatic progression. From 2003 to 2005 he was seconded to the department of Experimental (Discovery) Medicine at Alderley Park (AstraZeneca plc) where he provided translational medicine input to a number of early oncology projects in the invasion and metastasis biological effect area.
Since 2006 he has held the post of Senior Lecturer in Medical Oncology at the University of Glasgow and honorary consultant at the Beatson West of Scotland Cancer Centre. His clinical practice is the medical management of cancers of the prostate, bladder and kidney. His research commitments include the management of a large portfolio of phase I, II and III trials as well as collaborative translational research with scientists from the Beatson Institute. Since July 2011 he has been the Director of the Cancer Research UK Clinical Trials Unit based at the Beatson West of Scotland Cancer Centre. This Unit serves two functions: first, the set up and co-ordination of national and international multicentre cancer trials (supported by a CRUK programme grant). Second, the administration and conduct of cancer trials in which the Beatson participates.
He is the chief investigator of four academically sponsored clinical trials: the TOUCAN and PLUTO trials in metastatic urothelial cancer, the SAPROCAN trial in advanced prostate cancer and the ASPEN trial in renal cell carcinoma. He is also a collaborator in a number of other UK national trials in urological cancers, including POUT (urothelial cancer), TO-PARP (prostate), STAR and COSSAK (renal cell).